Europe GMP Cell Therapy Consumables Market

The Europe GMP cell therapy consumables market is expected to grow from US$ 4,827.85 million in 2022 to US$ 20,569.16 million by 2028; it is estimated to grow at a CAGR of 27.2% from 2022 to 2028.

Rise in Research & Development and Drug Discovery Drives Europe GMP Cell Therapy Consumables Market

Drug discovery is a long process that comprises various steps such as early discovery, preclinical phase, clinical phase, and regulatory approval. The process tremendously involves the use of cell therapy consumables to achieve the desired results. According to the World Health Organization, ~10 million deaths due to cancer were recorded in 2020, and the most common types of cancer are breast cancer, lung cancer, colon cancer, rectum cancer, and prostate cancer. Various research studies have shown positive outcomes of drugs that can effectively treat cancer, neurological disorders, autoimmune disorders, and other chronic disorders. Therefore, the rising prevalence of chronic disorders propels the demand for research and development (R&D) activities. In addition, the growing incidence of various rare disorders such as amyloidosis, Adrenoleukodystrophy, and Ehlers-Danlos syndrome has increased the R&D activities for drug development.

Moreover, numerous biotechnology companies operating in the GMP cell therapy consumables market are collaborating to accelerate R&D activities on a global level. For instance, in October 2022, Century Therapeutics and Bristol Myers Squibb announced the research collaboration and license agreement to develop and commercialize up to four induced pluripotent stem cells (“iPSC”) derived, engineered natural killer cell (“iNK”) and/or T cell (“iT”) programs for hematologic malignancies and solid tumors. Additionally, the rising demand for personalized and regenerative medicine has boosted the growth of the cell therapy consumables market. Thus, an increase in research & development activities along with a surge in drug discovery has tremendously increased the use of GMP cell therapy consumables, which is driving the growth of the GMP cell therapy consumables market across the region.

Europe GMP Cell Therapy Consumables Market Overview

The Europe GMP cell therapy consumables market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the global GMP cell therapy consumables market. The market growth in the region is due to increasing healthcare expenditure, rising incidence of cancer, increasing health awareness, and growing research and development. Germany is considered among the fastest-growing GMP cell therapy consumables market in Europe. The growing importance of GMP cell therapy consumables, along with the expansion of regional players, is aiding the market growth in Germany. Further, The Federal Statistical Office reported an increase in health expenditure in Germany which aids in research and development in the healthcare sector. According to German Trade and Invest (GTAI), Germany's biotech industry has been rapidly expanding for some years. On average, more than 710 companies are engaged in the biotechnology sector. Overall, the biotech sector revenue is increased by 36%, while R&D spending has increased by 37%. Germany has experienced a growth in the number of innovative pharmaceutical companies, drug manufacturers, contract research organizations (CROs), and small- and medium-sized biopharmaceutical companies.

Further, there have been remarkable innovations in the cell therapy segment in Germany. For instance, in 2021, Germany’s Federal Institute for Vaccines and Biomedicines (Paul-Ehrlich-Institut) granted RHEACELL national approval for its cell therapy product—AMESANAR—for use in patients having chronic wounds. Similarly, in June 2022, Bayer’s BlueRock Therapeutics established a European site for cell therapy innovation. BlueRock is currently engaged in a Phase I clinical trial for its novel cell therapy, BRT-DA01, for treating Parkinson’s disease. The rising government health expenditure, growing expansion of global players in Germany, and increasing product development by manufacturers are boosting the application of GMP cell therapy consumables, which is also boosting the growth of the Europe GMP cell therapy consumables market.

Europe GMP Cell Therapy Consumables Market Revenue and Forecast to 2028 (US$ Million)

Europe GMP Cell Therapy Consumables Strategic Insights

Strategic insights for the Europe GMP Cell Therapy Consumables provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe GMP Cell Therapy Consumables Report Scope

Europe GMP Cell Therapy Consumables Regional Insights

The geographic scope of the Europe GMP Cell Therapy Consumables refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Europe GMP Cell Therapy Consumables Market Segmentation

The Europe GMP cell therapy consumables market is segmented on the basis of product, cell therapy, process, end use, and country.

Based on product, the GMP cell therapy consumables market is segmented into kits, reagents/molecular biology reagents, growth factors/cytokines and interleukins (including protein and nucleic acid purification buffers), and others. The kits segment held the largest share of the Europe GMP cell therapy consumables market in 2022.

• Based on cell therapy, the GMP cell therapy consumables market is segmented into NK cell therapy, stem cell therapy, T-cell therapy, and others. The T-cell therapy segment registered the largest share of the Europe GMP cell therapy consumables market in 2022.
• Based on process, the market is segmented into cell collection and characterization/sorting and separation, cell culture and expansion/preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution/handling, process monitoring and control/readministration/quality assurance, and others. The cell collection and characterization/sorting and separation segment held the largest share of the Europe GMP cell therapy consumables market in 2022.
• Based on end use, the market is segmented into clinical, commercial, and research. The clinical segment held the largest share of the Europe GMP cell therapy consumables market in 2022.
• Based on country, the Europe GMP cell therapy consumables market is segmented into France, Italy, Germany, Spain, the UK, and the Rest of Europe. Germany dominated the Europe GMP cell therapy consumables market in 2022.

Bio-Techne Corp, BPS Bioscience Inc, Corning Inc, FUJIFILM Irvine Scientific Inc, Global Life Sciences Solutions USA LLC, Lonza Group AG, Merck KGaA, Miltenyi Biotec BV & Co KG, Sartorius AG, and Thermo Fisher Scientific Inc are the leading companies operating in the Europe cell therapy consumables market.